Already Registered? Log In Now
Not Registered?
Business Email:
Complete this form to enter the webcast.
Already Registered?
(* indicates required field)
Complete this form to enter the webcast.
(* indicates required field)
Business Email*:
First Name*:
Last Name*:
Title*:
Company Name*:
Street Address 1*:
City*:
State/Province*:
--
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Postal Code*:
Country*:
--
Afghanistan
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Macedonia, Republic of
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French Part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch Part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan
Tajikistan
Tanzania, United Republic of
Thailand
Timor-leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States Minor Outlying Islands
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Business Phone:
What is your Research Focus*:
--
Standard mAbs
Fusion Proteins
Antibody Drug Conjugates
Cell Line Development
checked
Yes, I want to receive marketing communications from SCIEX. By submitting your information, you agree that SCIEX may collect and further process your personal data in accordance with its Privacy Policy. You may object to receiving further information at any time.
checked
Yes, please subscribe me to BioPharm International's free e-newsletters.
By registering for this event, you agree to MJH Life Sciences ®
Terms and Conditions
,
Privacy Policy
, and understand your data will be used by MJH and its affiliates for amongst other things, alerting you to other services or products that you maybe interested in, and may be shared with or sold to third parties for their use, including possible contact with you through email or other communications, consistent with their respective privacy policy. If you do not agree to have your data used in this way, please contact
info@mjhassoc.com
.
*Denotes required.
SCIEX
Privacy Policy
Mass Information on Charge Variants is Changing the Game
Hear how from Fujifilm, Merck and Janssen
Thu, Sep 14, 2023 11:00 AM EDT
Event Overview:
In the development of biotherapeutics, genetic variations and post-translational modifications give each molecule a "personality”. Understanding these unique characteristics drives the development, manufacturability, and analytical methods used to monitor and control the quality attributes and testing requirements.
Join the discussion on strategies to address characterization of protein therapeutics at the intact level during process development. Learn more about the challenges in charge heterogeneity profiling, and how a disruptive approach using an integrated icIEF-UV/MS workflow with the Intabio ZT system is changing the game for scientists pushing the next generation of biotherapeutics forward.
Key Learning Objectives:
A disruptive approach for characterization of mAb charge variants in biopharmaceutical process development by icIEF-UV/MS
Learn how a new strategy can make a difference in assessing the impact cell culture conditions have on mAb quality and production.
Intact-level multi-attribute monitoring of complex biologics
Explore the potential of using icIEF-UV/MS for characterizing PQAs of complex biotherapeutics, including mAbs, ADCs and complex Fc fusion proteins.
Characterization of a biopharmaceutical
intensified process
utilizing icIEF-UV/MS to quantify advanced glycation end products as a source of color
Probe the cause of color change in protein therapeutics and learn how a cell line development group is utilizing the integrated icIEF-UV/MS workflow to monitor these advanced glycation events for product release
Who Should Attend:
Scientists in drug discovery, cell line development and protein therapeutics characterization
Featured Speakers
Greg Adams PhD
Sr. Director Global Analytical Strategy & Development
FujiFilm Diosynth Biotechnologies
Anita P. Liu PhD
Associate Principal Scientist
Merck
Kristen Nields PhD
Senior Scientist
Janssen
For any technical questions please contact Nicole Valle:
Nvalle@mjhevents.com
FAQs and System Test
Outlook ❯
Google ❯